New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-AHK vs Exenatide

Pal-AHK vs Exenatide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-AHK
GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
Summary
Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Half-Life
Extended (lipid depot effect in stratum corneum)
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
Admin Route
Topical
SubQ
Research
Typical Dose
0.01–0.05% in formulation
5 mcg, titrate to 10 mcg
Frequency
Once or twice daily
Twice daily
Key Benefits
  • Enhanced skin penetration vs. unmodified AHK-Cu
  • Stimulates dermal collagen and elastin production
  • Promotes hair follicle anagen phase
  • Antioxidant and wound healing activity
  • Firming and plumping effect on aging skin
  • Improved bioavailability via lipid bilayer incorporation
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
Side Effects
  • Generally well-tolerated
  • Mild irritation at high concentrations in sensitive skin
  • Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
Stacks With